Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

JNJ 102.40 +0.44 (0.43%)
price chart
Johnson & Johnson facing massive class action
Medical giant Johnson & Johnson is facing its third class action in Australia in as many years, with a case filed in the Federal Court yesterday which relates to a product called transvaginal mesh.
Johnson & Johnson Agrees to Settle Five Rispersal Suits
Johnson & Johnson agreed to settle five lawsuits over claims that its antipsychotic drug Risperdal caused increased breast-tissue growth in boys.
Done with Creative Review, J&J Turns Sights to Global Media Review
Johnson & Johnson has concluded its global creative agency review and is preparing to launch a global media review in markets not already in review, including North America, company executives said today.
Johnson & Johnson diabetes drug effective in high risk patients
An experimental treatment for type 2 diabetes developed by Johnson & Johnson proved effective at reducing blood sugar in patients on long-term insulin therapy and at high risk for heart problems, according to a study presented on Tuesday.
J.&J.'s Costs Take a Toll on Its Profit
Revenue rose 6.5 percent to $17.05 billion, pushed up nearly 6 percent by sales from Synthes Inc., a maker of surgical trauma equipment and orthopedic implants.
Johnson & Johnson Tops Street in 3Q, Lifts Outlook  Fox Business
Johnson & Johnson Tops Forecasts on Lower Profit
Five reasons to like Johnson & Johnson
Johnson & Johnson has made headlines over the past couple of years - for all the wrong reasons. Plagued by quality control problems and costly product recalls affecting key brands such as Tylenol, Benadryl and Motrin, the health care giant's reputation ...
Tylenol and the Legacy of J&J's James Burke
This post is in partnership with Knowledge@Wharton, the online research and business analysis journal of the Wharton School of the University of Pennsylvania.
Johnson & Johnson: Dividend Stock Analysis
JNJ is another US mammoth (both in terms of age and size) operating in the manufacturing, marketing, distribution of consumer goods.
J&J's Global Creative Review Nears Finish
Johnson & Johnson is close to concluding its global review of creative responsibilities for its over-the-counter brands and sources expect the bulk of the business to be consolidated at three roster shops: DDB, BBDO and JWT.
Gores Group to Buy Johnson & Johnson Unit
The Gores Group on Monday said that it has agreed to acquire the maker of a medical device that's used to treat blood cancer from a unit of New Jersey health care conglomerate Johnson & Johnson. Therakos is a 25-year-old company based in Raritan, N.J ...